PharmaEssentia

► Home ﹥Our Projects ﹥Bio-Tech Products ﹥PEG

Innovative Long-Acting Protein Biologic Drug Project
PEGylaltion Technology Platform
In the field of protein drug design, the process of so-called 'PEGylaltion' of the therapeutic protein preserves its biological activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. PharmaEssentia's PEGylaltion Technology Platform is designed to increase the protein drug's effective size, slowing its circulation in the blood. Utilizing its innovative 40K PEG and its novel PEGylaltion technology platform of combining protein engineering and PEG-related chemistry, PharmaEssntia creates new products for better disease treatment. Compared with others on the market, the long-acting protein drugs produced by PharmaEssentia possess the most effective PK/PD data as well as least number of side-effects, as these PEG-proteins are designed as predominate single forms without other isomers which may induce severe side-effects.

Simply speaking, PharmaEssentia's novel PEGylaltion technology platform provide the following advantages to produce more effective protein drugs when compared to other PEGylated protein design processes:

1. Improved PEG molecular synthesis method
2. Newly-invented 40K PEG molecular, 40K, is generally considered to be the upper size limit of the PEG molecular that
can be absorbed by humans
3. The single-site-specific conjugation PEGylaltion

Not only the PEG-protein drugs have the commercial value, but also the PEGylaltion technology platform does.

PharmaEssentia is actively seeking collaborative opportunities in the field of PEGylated proteins, and the company has already received interest from a number of prominent international pharmaceutical companies focusing on the development of protein drugs.

Our Strategy
PharmaEssentia is focused on the development of long-acting forms of existing blockbuster protein drugs, a market segment of over US$1 billion annually. The company is now developing five PEGylated protein drugs, which it calls its Big Five,' with its P1101 currently undergoing US FDA IND filing, and is scheduled to enter its Phase I clinical trial in Q1, 2009. At the same time, based on a cost-effective approach, PharmaEssentia is also utilizing experience gained from developing P1101 to build and advance the development process of the other four drugs; the 'PEG-Four' project. The following figure shows the overall timeline for the Big Five project.

Timeline for Big Five project